查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1303915

乳腺癌液体活检市场：按生物标誌物、最终用户划分 - 2023-2030 年全球预测

Breast Cancer Liquid Biopsy Market by Biomarker, End-User - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

全球乳腺癌液体活检市场预计将大幅增长，预计2023年将达到4.9429亿美元，复合年增长率为19.42%，预计2030年将达到17.1415亿美元。

FPNV定位矩阵

FPNV定位矩阵对于评估全球乳腺癌液体活检市场至关重要。通过检验业务策略和产品满意度等关键指标，它可以对供应商进行全面评估，使用户能够根据自己的特定需求做出资讯的决策。这种高级分析将供应商分为四个像限，并取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市场份额分析

市场份额分析可以深入了解供应商在特定市场领域的当前地位。比较供应商对总收入、基本客群和其他关键指标的贡献，可以帮助公司更好地了解他们在争夺市场份额时的表现以及面临的情况。该分析还揭示了特定行业的竞争程度、积累和合併的优势以及研究基准年的合併特征。

本报告提供了以下几点见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开发：提供有关利润丰厚的新兴市场的详细资讯，并分析其在成熟市场的渗透率。

3. 市场多元化：提供有关新产品发布、未开发地区、最新发展和投资的详细资讯。

4.市场趋势：全面了解COVID-19、俄罗斯-乌克兰衝突和高通胀的累积影响。

5、竞争评估与资讯：对主要企业的市场份额、战略、产品、认证、法规状况、专利状况、製造能力等进行综合评价。

6. 产品开发和创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告回答了以下问题：

1.全球乳腺癌液体活检市场规模及预测是多少？

2.在预测期内，COVID-19 对全球乳腺癌液体活检市场的抑制要素和影响有哪些？

3.在预测期内，全球乳腺癌液体活检市场需要投资哪些产品/细分市场/应用/领域？

4.全球乳腺癌液体活检市场的竞争策略是什么？

5.全球乳腺癌液体活检市场的技术趋势和法律规范是什么？

6.全球乳腺癌液体活检市场主要供应商的市场份额是多少？

7. 哪些型态和战略倡议被认为适合进入全球乳腺癌液体活检市场？

目录

第1章前言

第2章调查方法

第3章执行摘要

第4章市场概况

第5章市场洞察

  • 市场动态
    • 促进因素
      • 全球罹患率正在上升
      • 对非侵入性乳腺癌治疗的需求不断增长
      • 用于液体活检研究和开发的资金的可用性
    • 抑制因素
      • 乳腺癌液体活检的费用很高。
    • 机会
      • 乳腺癌液体活检早期检测技术进展
      • 增加乳腺癌液体活检试剂的批准
    • 任务
      • 严峻的法规挑战和糟糕的报销政策
  • 市场趋势
  • COVID-19 的累积影响
  • 俄罗斯-乌克兰衝突的累积影响
  • 高通胀的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法律规范
  • 客户定制

第6章按生物标誌物分類的乳腺癌液体活检市场

  • 游离DNA
  • 迴圈肿瘤细胞
  • 细胞外囊泡

第7章乳腺癌液体活检市场：按最终用户分类

  • 医院及医生检查室
  • 参考实验室

第8章美洲乳腺癌液体活检市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第9章亚太乳腺癌液体活检市场

  • 澳大利亚
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第10章欧洲、中东和非洲乳腺癌液体活检市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第11章竞争形势

  • FPNV定位矩阵
  • 市场份额分析：主要企业
  • 竞争情景分析：主要企业

第12章上市公司名单

第13章附录

  • 讨论指南
  • 关于许可和定价
Product Code: MRR-437D4595856D

The Global Breast Cancer Liquid Biopsy Market is forecasted to grow significantly, with a projected USD 494.29 million in 2023 at a CAGR of 19.42% and expected to reach a staggering USD 1,714.15 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Breast Cancer Liquid Biopsy Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Breast Cancer Liquid Biopsy Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Biomarker, market is studied across Cell-free DNA, Circulating Tumor Cells, and Extracellular Vesicles. The Cell-free DNA is projected to witness significant market share during forecast period.

Based on End-User, market is studied across Hospitals & Physician Laboratories and Reference Laboratories. The Reference Laboratories is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.74% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Breast Cancer Liquid Biopsy Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Breast Cancer Liquid Biopsy Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Breast Cancer Liquid Biopsy Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Breast Cancer Liquid Biopsy Market?

4. What is the competitive strategic window for opportunities in the Global Breast Cancer Liquid Biopsy Market?

5. What are the technology trends and regulatory frameworks in the Global Breast Cancer Liquid Biopsy Market?

6. What is the market share of the leading vendors in the Global Breast Cancer Liquid Biopsy Market?

7. What modes and strategic moves are considered suitable for entering the Global Breast Cancer Liquid Biopsy Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Breast Cancer Liquid Biopsy Market, by Biomarker, 2022 vs 2030
  • 4.3. Breast Cancer Liquid Biopsy Market, by End-User, 2022 vs 2030
  • 4.4. Breast Cancer Liquid Biopsy Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of breast cancer worldwide
      • 5.1.1.2. Increasing demand for non-invasive breast cancer treatment
      • 5.1.1.3. Availability of funding for liquid biopsy R&D
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of breast cancer liquid biopsy
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements in early-stage detection of breast cancer liquid biopsy
      • 5.1.3.2. Increasing breast cancer liquid biopsy reagent approvals
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory issues and poor reimbursement policies
  • 5.2. Market Trends
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization

6. Breast Cancer Liquid Biopsy Market, by Biomarker

  • 6.1. Introduction
  • 6.2. Cell-free DNA
  • 6.3. Circulating Tumor Cells
  • 6.4. Extracellular Vesicles

7. Breast Cancer Liquid Biopsy Market, by End-User

  • 7.1. Introduction
  • 7.2. Hospitals & Physician Laboratories
  • 7.3. Reference Laboratories

8. Americas Breast Cancer Liquid Biopsy Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Breast Cancer Liquid Biopsy Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Breast Cancer Liquid Biopsy Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
  • 11.2. Market Share Analysis, By Key Player
  • 11.3. Competitive Scenario Analysis, By Key Player

12. List of Company Mentioned

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. BREAST CANCER LIQUID BIOPSY MARKET RESEARCH PROCESS
  • FIGURE 2. BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2022 VS 2030
  • FIGURE 3. BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2022 VS 2030 (%)
  • FIGURE 5. BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2022 VS 2030 (%)
  • FIGURE 6. BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 7. BREAST CANCER LIQUID BIOPSY MARKET DYNAMICS
  • FIGURE 8. BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 9. BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 11. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 12. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. BREAST CANCER LIQUID BIOPSY MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 15. BREAST CANCER LIQUID BIOPSY MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. BREAST CANCER LIQUID BIOPSY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 5. BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CELL-FREE DNA , BY REGION, 2018-2030 (USD MILLION)
  • TABLE 6. BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR CELLS , BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXTRACELLULAR VESICLES , BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 9. BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY HOSPITALS & PHYSICIAN LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 12. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 13. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 14. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 15. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 16. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 17. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 18. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 19. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 20. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 21. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 23. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 24. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 25. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 27. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 28. AUSTRALIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 29. AUSTRALIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. CHINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 31. CHINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. INDIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 33. INDIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. INDONESIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 35. INDONESIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. JAPAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 37. JAPAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. MALAYSIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 39. MALAYSIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. PHILIPPINES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 41. PHILIPPINES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. SINGAPORE BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 43. SINGAPORE BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. SOUTH KOREA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 45. SOUTH KOREA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. TAIWAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 47. TAIWAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. THAILAND BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 49. THAILAND BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. VIETNAM BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 51. VIETNAM BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 54. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. DENMARK BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 56. DENMARK BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. EGYPT BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 58. EGYPT BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. FINLAND BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 60. FINLAND BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. FRANCE BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 62. FRANCE BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. GERMANY BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 64. GERMANY BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. ISRAEL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 66. ISRAEL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. ITALY BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 68. ITALY BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. NETHERLANDS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 70. NETHERLANDS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. NIGERIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 72. NIGERIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. NORWAY BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 74. NORWAY BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. POLAND BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 76. POLAND BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. QATAR BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 78. QATAR BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. RUSSIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 80. RUSSIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. SAUDI ARABIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 82. SAUDI ARABIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. SOUTH AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. SPAIN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 86. SPAIN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. SWEDEN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 88. SWEDEN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. SWITZERLAND BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 90. SWITZERLAND BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. TURKEY BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 92. TURKEY BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED ARAB EMIRATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED ARAB EMIRATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED KINGDOM BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED KINGDOM BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. BREAST CANCER LIQUID BIOPSY MARKET, FPNV POSITIONING MATRIX, 2022
  • TABLE 98. BREAST CANCER LIQUID BIOPSY MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 99. BREAST CANCER LIQUID BIOPSY MARKET LICENSE & PRICING